Amgen's $1.3 Bil. Acquisition Of Tularik Would Yield Two Late-Stage Oncologics
This article was originally published in The Pink Sheet Daily
Executive Summary
Tularik would broaden Amgen's oncology portfolio to small molecules with compounds for hepatocellular carcinoma, and esophageal and gastric cancers. The deal is one-tenth the size of Amgen's last acquisition – the $10 bil. Immunex purchase.
You may also be interested in...
Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”
Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”
Amgen Venture Capital Fund Starts With $100 Mil.
Amgen Ventures will focus investment in early biotech companies researching areas of "current therapeutic interest to Amgen," including oncology, metabolic disorders and inflammation.